Cabaletta Bio, Inc.
Cabaletta Bio, Inc. is a clinical-stage biotechnology company developing engineered T-cell therapies for autoimmune diseases. Its core platform, CABA, is designed to selectively eliminate disease-causing B cells and plasma cells, with lead programs such as rese-cel being studied in indications including pemphigus vulgaris, myositis, systemic lupus erythematosus, generalized myasthenia gravis, systemic sclerosis, and related autoimmune disorders. The company has not yet generated product revenue and remains focused on advancing clinical trials, regulatory interactions, and manufacturing readiness. Cabaletta is also building a commercial-scale manufacturing strategy through CDMO partnerships and potential internal capabilities to support future supply if its programs are approved.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueAutologous engineered T-cell therapy programs centered on rese-cel for autoimmune diseases.
RESET-branded clinical studies evaluating rese-cel across multiple autoimmune indications.
The CABA platform used to design and advance targeted cell therapies against pathogenic B cells and plasma cells.
Process transfer, scale-up, and supply-chain readiness work with CDMOs and potential internal facilities.
Customers
Cabaletta does not currently sell commercial products, so its near-term 'customers' are primarily clinical trial sites, investigators, and patients enrolled in its studies. If approved, the eventual buyers would be specialty physicians, hospitals, and treatment centers managing severe autoimmune diseases that require advanced immunotherapy. Payers and health systems would also be important decision-makers because these therapies are likely to be high-cost, specialized treatments. The company’s business model depends on convincing clinicians that its targeted cell therapies can offer meaningful benefit versus existing immunosuppressive or biologic options.
Patients with autoimmune diseases such as pemphigus vulgaris, myositis, SLE, MG, and systemic sclerosis who enroll in RESET studies to access investigational therapy.
Academic and specialty centers that recruit, treat, and monitor patients in Cabaletta’s clinical programs.
Rheumatologists, neurologists, dermatologists, and related specialists who would prescribe or refer patients if products are approved.
Centers capable of handling cell therapy administration, monitoring, and patient support for complex autoimmune indications.
Insurers and health systems that would determine access and coverage for a high-cost advanced therapy.
Strategy
Cabaletta’s strategy is to advance rese-cel through multiple RESET clinical trials and build enough clinical evidence to support regulatory approval in autoimmune diseases. A major priority is manufacturing readiness, including transfer of an improved process to Lonza and evaluation of multiple scale-up options such as additional CDMOs, leased facilities, or an owned manufacturing site. The company is also broadening the pipeline across several autoimmune indications, which can increase the value of the platform if one program validates the approach. Because it has no product revenue, capital preservation and access to financing remain central to executing the development plan.
Clinical proof-of-concept is the main value driver for a pre-revenue biotech and is required for any regulatory path.
Cell therapy commercialization depends on reliable, compliant, and scalable supply.
Multiple autoimmune indications can diversify clinical risk and increase the long-term commercial opportunity.
The company expects continued cash burn before any product revenue and needs capital to fund trials and manufacturing.
Geography
Cabaletta is headquartered in the United States and its reported operating footprint is centered on U.S.-based clinical development, manufacturing coordination, and corporate functions. The company also references international operations in its staffing and cost discussion, indicating some non-U.S. activity tied to development and manufacturing support. Manufacturing readiness depends on third-party partners such as Lonza and Minaris, so geography matters mainly through where clinical sites, CDMOs, and regulatory interactions are located. Because the company is pre-revenue, there is no disclosed country revenue mix to map.
Risks
Cabaletta faces the classic risks of an early-stage biotech: clinical failure, regulatory delay, and the possibility that its programs never reach commercialization. Its dependence on third-party manufacturers creates supply, quality, and facility-approval risk, and any disruption could delay trials or future launch plans. Even if approved, the company may face physician reluctance, payer pressure, and competition from other therapies in development for the same autoimmune diseases. Because it has no product revenue and limited operating history, financing risk and dilution remain material until the business can generate durable clinical or commercial value.
- Early-stage clinical development riskImpact: CriticalLikelihood: High
The company is still testing whether rese-cel can show safety and efficacy across autoimmune indications.
Exposure: Lead programs and pipeline value
- Financing and dilution riskImpact: HighLikelihood: High
The company has no product revenue and will need additional capital to fund trials and manufacturing scale-up.
Exposure: Shareholder dilution and liquidity
- Manufacturing and supply chain dependenceImpact: HighLikelihood: Medium
Cabaletta relies on CDMOs and third parties for production, release testing, and process transfer.
Exposure: Clinical supply and future commercialization
- Competition in autoimmune therapeuticsImpact: High
Other biopharmaceutical companies are developing therapies for PV, MG, SLE, myositis, SSc, gMG, and MS.
Exposure
Accounting
Judgemental itemsClinical and manufacturing costs are expensed as incurred, with some vendor costs recognized based on progress estimates.
Impact: Can cause significant quarterly fluctuation in operating expenses and cash burn
Employee equity awards are a recurring non-cash cost in a talent-intensive biotech.
Impact: Affects reported operating loss and comparability across periods
Finance lease arrangements related to manufacturing agreements increase interest expense and liabilities.
Impact: Impacts leverage presentation and operating cost structure
The company holds substantial cash and investment balances that generate interest income.
Impact: Can partially offset operating losses and vary with cash deployment timing
Similar listed companies
Publicly listed companies with a comparable business focus.
AbCellera Biologics Inc.
ABCL · Pharmaceutical Preparations
Zura Bio Ltd
ZURA · Biological Products, (No Diagnostic Substances)
Zura Bio Ltd is a U.S.-based clinical-stage biopharmaceutical company focused on developing antibody-based therapies for immune-mediated diseases.
Atara Biotherapeutics, Inc.
ATRA · Biological Products, (No Diagnostic Substances)
Atara Biotherapeutics is a U.S.-based biotechnology company focused on T-cell immunotherapy built around its allogeneic Epstein-Barr virus (EBV) T-cell platform.
BioAtla, Inc.
BCAB · Biological Products, (No Diagnostic Substances)
Estrella Immunopharma, Inc.
ESLAW · Biological Products, (No Diagnostic Substances)
Fate Therapeutics, Inc
FATE · Biological Products, (No Diagnostic Substances)
Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies built from human induced pluripotent stem cells (iPSCs).
Last updated: 24/09/2026